TIMP2 and breast cancer: In 2019, Wang and his colleagues reported significantly elevated transcriptional expression levels of TIMP-2 among tumor sites from 1097 BC cases compared to 114 normal controls, which conflicts with, yet holds greater persuasiveness in terms of sample size, than the findings presented by Ozdemir, which involved only 96 BC patients and 35 healthy individuals [19].